A PROSTVAC(TM) abstract has been accepted for an oral presentation at the European CanCer Organisation (ECCO), ECCO 15 - 34th ESMO Congress, taking place in Berlin September 20-24 2009.
Ongoing PROSTVAC(TM) studies
There are a number of ongoing clinical studies with PROSTVAC(TM) in both early and late stage prostate cancer, all of which are funded and conducted by NCI under the ongoing collaboration with Bavarian Nordic.
Ongoing studies with active patient enrolling: - Phase II study comparing the radioactive drug, samarium with or without PROSTVAC(TM) therapy in men with metastatic prostate cancer - Phase II study comparing antihormone therapy (flutamide) with or without PROSTVAC(TM) therapy in men with non-metastatic prostate cancer Ongoing studies with enrolment completed: - Phase II study investigating PROSTVAC(TM) in men with PSA progress after local therapy (surgery and/or radiation) - Phase I dose-escalation, combination study with PROSTVAC(TM) and MDX-010 (CTL4-antibody) in men with metastatic prostate cancer - Phase I study investigating PROSTVAC(TM) by intraprostatic injection in patients with progressive or locally recurrent prostate cancer
This announcement includes "forward-looking statements" that involve
risks, uncertainties and other factors, many of which are outside of our
control that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to
|SOURCE Bavarian Nordic A/S|
Copyright©2009 PR Newswire.
All rights reserved